← All trials
NCT06916884
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 11, 2024
- Primary completion
- May 11, 2025
- Completion date
- Jun 11, 2025
- First posted
- Apr 8, 2025
- Last posted
- Apr 8, 2025
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Laboratorios Silanes S.A. de C.V.Lead sponsor
- Unidad de Medicina Especializada SMAOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.